Extended Data Fig. 6: CCM3 acts as a gatekeeper in focal adhesions.
a, Pharmacological inhibition of FAK and Src reverts YAP/TAZ nuclear translocation in Cer-CAFs and b, inhibits Cer-CAF-induced contraction observed after loss of CCM3 in Cer-CAFs. Scale bar, 50 μm. c, Cell viability assay of V-CAFs treated with FAK and Src inhibitors. n = 3 independent experiments. Line and error bars indicate mean ± s.d. d, Flow cytometry analysis of total β1-integrin (K-20) and activated β1-integrin (12g10) on the cell surface of HN-CAFs, V-CAFs, and Cer-CAFs. e, siRNA-transfected V-CAFs plated on soft (0.5 kPa) and hard (50 kPa) hydrogels. V-CAFs were stained for active β1-integrin using the 12g10 antibody. Quantification of the focal adhesion size based on the active β1-integrin (12g10) staining. n: individual focal adhesions (0.5 kPa: siCtr, 336; siCCM3, 326. 50 kPa: siCtr, 365; siCCM3, 361). Line and error bars indicate mean ± s.d. ****P < 0.0001; Kruskal–Wallis non-parametric tests, following up multiple-comparison post-hoc test, two-sided. Statistical data are provided in the source data.
